August 15, 2015Open Access

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

Key Points

Key points are not available for this paper at this time.

Abstract

This final report demonstrates that RTX remains well tolerated over time and multiple courses. No new safety risks were identified and there was no increase in the rate of any types of adverse events with prolonged exposure to RTX during 11 years of observation.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Vollenhoven et al. (Sat,) studied this question.

synapsesocial.com/papers/69dcdf2a854f360ad63594be https://doi.org/https://doi.org/10.3899/jrheum.150051

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register2007 · 561 citations